We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

35 hedge funds and large institutions have $10.8M invested in Axsome Therapeutics in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

351% more call options, than puts

Call options by funds: $284K | Put options by funds: $63K

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

0% more funds holding

Funds holding: 35 → 35 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.63% less ownership

Funds ownership: 13.46% → 12.84% (-0.63%)

12% less capital invested

Capital invested by funds: $12.2M → $10.8M (-$1.4M)

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

Holders
35
Holders Change
–
Holders Change %
0%
% of All Funds
0.78%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
5
Reduced
10
Closed
10
Calls
$284K
Puts
$63K
Net Calls
+$221K
Net Calls Change
+$214K

Top Buyers

1
ACM
Alethea Capital Management
Washington
+$1.19M
2
Millennium Management
Millennium Management
New York
+$1.02M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$823K
4
ECM
Endurant Capital Management
California
+$375K
5
OAM
Oxford Asset Management
United Kingdom
+$243K

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.44M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$770K
3
OPPM
Opus Point Partners Management
New York
-$415K
4
JP Morgan Chase
JP Morgan Chase
New York
-$140K
5
SCM
Sio Capital Management
New York
-$117K
Name Holding Trade Value Shares
Change 		Change in
Stake
SSB
26
Sandy Spring Bank
Maryland
$25K – – –
Morgan Stanley
27
Morgan Stanley
New York
$17K -$3.17K -963 -14%
MAM
28
Meeder Asset Management
Ohio
$7K -$4.94K -1,501 -37%
Bank of America
29
Bank of America
North Carolina
$7K +$7.66K +2,327 New
SWM
30
SeaCrest Wealth Management
New York
$6K – – –
LTFS
31
Ladenburg Thalmann Financial Services
Florida
$4K -$5.41K -1,645 -51%
TRCT
32
Tower Research Capital (TRC)
New York
$3K +$2.92K +888 New
First Manhattan
33
First Manhattan
New York
$3K +$3.62K +1,100 New
Simplex Trading
34
Simplex Trading
Illinois
$1K +$987 +300 +300%
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
$8 – – –
Fidelity Investments
36
Fidelity Investments
Massachusetts
– -$1.44M -416,252 Closed
OPPM
37
Opus Point Partners Management
New York
– -$415K -120,150 Closed
JP Morgan Chase
38
JP Morgan Chase
New York
– -$140K -40,698 Closed
Walleye Trading
39
Walleye Trading
New York
– -$98K -28,323 Closed
JMFC
40
J.M. Forbes & Co
Massachusetts
– -$52K -15,066 Closed
IP
41
Intellectus Partners
California
– -$36K -10,400 Closed
ML
42
McAdam LLC
Pennsylvania
– -$7K -2,000 Closed
WIA
43
Westbourne Investment Advisors
Maryland
– -$3K -1,000 Closed
IGGA
44
Iron Gate Global Advisors
Utah
– -$1K -250 Closed
1
2

AXSM Hedge Fund Activity: Q4 2018 in Review

35 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2018, worth a combined $10.8M — down 12% from $12.2M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new AXSM positions and 10 closed out — a net gain of 1 holder — while 5 added to existing stakes and 10 trimmed.

The largest buyer was Alethea Capital Management, adding an estimated $1.19M. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.44M sold.

  • 35 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2018, unchanged from Q3 2018.
  • Funds reported $10.8M of Axsome Therapeutics stock for Q4 2018, down 12% quarter-over-quarter.
  • 11 funds opened new Axsome Therapeutics positions in Q4 2018 and 10 closed out, a net change of +1 holder.
  • The largest Axsome Therapeutics buyer in Q4 2018 was Alethea Capital Management, an estimated $1.19M added.
  • The largest Axsome Therapeutics seller in Q4 2018 was Fidelity Investments, an estimated $1.44M sold.

Based on aggregated 13F filings for Q4 2018.